MADRID, Spain and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update on recent developments.
Mon, 13 May 2024 07:01:00 GMT Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) ...
Thu, 09 May 2024 03:01:00 GMT Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented ... s subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the ...
Fri, 26 Apr 2024 13:30:00 GMT For more information, refer to "Use of Non-GAAP Financial Measures" and "Reconciliations of Non-GAAP Results" at the end of this press release.
Thu, 25 Apr 2024 04:56:00 GMT North Texas-based airlines Southwest and American released their first-quarter earnings reports Thursday morning ... CEO Robert Isom said in a press release. But American officials in the release ...
Wed, 24 Apr 2024 13:15:00 GMT We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
